Hence, great effort should focus on the emerging hotpot IL-6-receptor antagonist, as well as targeting leukotriene B4 and nuclear factor-κB (NF-κB) signalling in different PAH animal models and clinical trials. This evidence concerns the gene NFKB1 and pulmonary arterial hypertension.